A Comparative Study of the Healing Status by the Use of Alvogyl and Platelet-Rich Fibrin in the Treatment of Alveolar Osteitis: A Randomized Double-Blind Controlled Clinical Trial

Alveolar osteitis, commonly referred to as dry socket, is a frequent painful complication following tooth extraction. It is characterized by persistent or increasing postoperative pain, typically developing within the first few days after extraction, and may be associated with an empty extraction socket, foul odour, and delayed local healing. The condition can substantially affect patient comfort and quality of life and may require additional clinical management.

Several treatment approaches have been used for alveolar osteitis, including socket irrigation, local dressings, analgesics, antibiotics in selected circumstances, and regenerative materials. Alvogyl is a commonly used intra-alveolar dressing that is intended to provide symptomatic relief and protect the affected socket. Although it can provide rapid pain relief, concerns have been raised regarding its potential effect on the rate of socket healing.

Platelet-rich fibrin (PRF) is an autologous platelet concentrate prepared from the patient's own venous blood without the use of anticoagulants. During centrifugation, a fibrin-rich matrix containing platelets and leukocytes is formed. This matrix serves as a scaffold for tissue repair and provides a sustained release of biologically active mediators, including growth factors involved in angiogenesis, cellular proliferation, and wound healing. PRF has therefore been investigated as a regenerative treatment for extraction socket healing and alveolar osteitis.

Previous clinical studies comparing Alvogyl and PRF have reported differences in pain relief and socket healing. Some evidence suggests that Alvogyl may provide more rapid symptomatic pain relief, whereas PRF may promote more favourable or faster clinical healing. However, variation in study findings and treatment protocols indicates a need for further controlled clinical investigation.

This study is designed as a randomized, double-blind, controlled clinical trial comparing Alvogyl with PRF for the treatment of alveolar osteitis following third molar extraction. Eligible participants will be randomly allocated to receive either Alvogyl or an autologous PRF membrane. Both treatment groups will undergo standardized socket irrigation and debridement before placement of the assigned treatment. The extraction socket will subsequently be secured using sutures.